Modality
Degrader
MOA
USP1i
Target
SGLT2
Pathway
mTOR
MyelofibrosisEndometrial CaPV
Development Pipeline
Preclinical
~Jun 2013
→ ~Sep 2014
Phase 1
~Dec 2014
→ ~Mar 2016
Phase 2
~Jun 2016
→ ~Sep 2017
Phase 3
Dec 2017
→ Aug 2030
Phase 3Current
NCT06813958
1,617 pts·Endometrial Ca
2017-12→TBD·Not yet recruiting
NCT05033744
1,617 pts·PV
2022-05→2030-08·Active
NCT06557258
2,306 pts·Endometrial Ca
2025-04→2030-03·Recruiting
5,540 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-12-028mo awayPDUFA· Myelofibrosis
2030-03-274.0y awayPh3 Readout· Endometrial Ca
2030-08-114.4y awayPh3 Readout· PV
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Not yet…
P3
Active
P3
Recruit…
Catalysts
PDUFA
2026-12-02 · 8mo away
Myelofibrosis
Ph3 Readout
2030-03-27 · 4.0y away
Endometrial Ca
Ph3 Readout
2030-08-11 · 4.4y away
PV
RecruitingActiveNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06813958 | Phase 3 | Endometrial Ca | Not yet recr... | 1617 | 6MWD |
| NCT05033744 | Phase 3 | PV | Active | 1617 | SRI-4 |
| NCT06557258 | Phase 3 | Endometrial Ca | Recruiting | 2306 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| AMG-9052 | Amgen | Phase 2/3 | CDK2 | |
| Datozumab | Regeneron | Phase 1 | B7-H3 | |
| GMA-729 | Genmab | Phase 2 | BCL-2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 |